Peptide Product Composition: Glucagon Half-Life and Its Impact on Formulation
Abstract: Glucagon’s short half-life ( 3–6 min) critically dictates peptide product composition, requiring advanced formulation technologies (e.g., microsphere encapsulation, PEGylation) to extend stability. Market trends show a shift toward long-acting GLP-1/glucagon dual agonists, with brands like Novo Nordisk and Eli Lilly leading. Product comparisons highlight trade-offs: immediate-release vs. sustained-release systems. Key parameters include purity (>98%), bioactivity, and excipient compatibility. Applications span diabetes, obesity, and congenital hyperinsulinism. Industry growth (CAGR 8.5%) demands rigorous factory GMP certifications and cold-chain logistics. Selection criteria prioritize half-life optimization, regulatory approvals (FDA/EMA), and clinical data transparency.